Coherus All But Checks Out Of Biosimilars With Meitheal Adalimumab Deal
Yusimry Biosimilar Divested To Hong Kong King-Friend For $40m Upfront
Meitheal Pharmaceuticals can begin preparations for a seminal moment, the firm’s first marketed US biosimilar, as it snapped up rights to Humira rival Yusimry from Coherus BioSciences.
